BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 12407450)

  • 1. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
    Ozören N; El-Deiry WS
    Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand.
    Ozoren N; Kim K; Burns TF; Dicker DT; Moscioni AD; El-Deiry WS
    Cancer Res; 2000 Nov; 60(22):6259-65. PubMed ID: 11103780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells.
    Sun SY; Yue P; Hong WK; Lotan R
    Cancer Res; 2000 Dec; 60(24):7149-55. PubMed ID: 11156424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
    Ravi R; Bedi A
    Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Casein kinase I attenuates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by regulating the recruitment of fas-associated death domain and procaspase-8 to the death-inducing signaling complex.
    Izeradjene K; Douglas L; Delaney AB; Houghton JA
    Cancer Res; 2004 Nov; 64(21):8036-44. PubMed ID: 15520213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trail-induced apoptosis in Type I leukemic cells is not enhanced by overexpression of bax.
    Jia L; Patwari Y; Kelsey SM; Newland AC
    Biochem Biophys Res Commun; 2001 May; 283(5):1037-45. PubMed ID: 11355877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.
    Fulda S; Meyer E; Debatin KM
    Cancer Res; 2000 Jul; 60(14):3947-56. PubMed ID: 10919673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
    Sun SY; Yue P; Zhou JY; Wang Y; Choi Kim HR; Lotan R; Wu GS
    Biochem Biophys Res Commun; 2001 Jan; 280(3):788-97. PubMed ID: 11162590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
    Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
    Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways.
    Suliman A; Lam A; Datta R; Srivastava RK
    Oncogene; 2001 Apr; 20(17):2122-33. PubMed ID: 11360196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
    Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of mitochondrial DNA-deficient cells to TRAIL: role of Bax in TRAIL-induced apoptosis.
    Kim JY; Kim YH; Chang I; Kim S; Pak YK; Oh BH; Yagita H; Jung YK; Oh YJ; Lee MS
    Oncogene; 2002 May; 21(20):3139-48. PubMed ID: 12082629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria.
    Zhang XD; Zhang XY; Gray CP; Nguyen T; Hersey P
    Cancer Res; 2001 Oct; 61(19):7339-48. PubMed ID: 11585775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
    Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
    Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
    Chawla-Sarkar M; Bae SI; Reu FJ; Jacobs BS; Lindner DJ; Borden EC
    Cell Death Differ; 2004 Aug; 11(8):915-23. PubMed ID: 15118763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.
    Aggarwal BB; Bhardwaj U; Takada Y
    Vitam Horm; 2004; 67():453-83. PubMed ID: 15110190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
    Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
    Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I; Ucur E; Herzer K; Okouoyo S; Ridder R; Krammer PH; von Knebel Doeberitz M; Debatin KM
    Cancer Res; 2003 Jun; 63(12):3112-20. PubMed ID: 12810637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
    Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
    Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.